Europe Health Screening Market, By Test Type (Cholesterol Tests, Diabetes Test, Cancer Screening, General Check Up Test, STDs, Blood Pressure Test and Others), Package Type (Basic Health Screening, Senior Citizen Profile, Women Health Check, Men Health Check, Heart Check, Diabetes Check and Others), Panel Type (Multi-Test Panels and Single-Test Panels), Sample Type (Blood, Urine, Serum, Saliva and Others), Technology (Immunoassays, Medical Imaging, QPCR (Quantitative Polymerase Chain Reaction), Q-FISH (Quantitative Fluorescence, in Situ Hybridization), TRF (Terminal Restriction Fragment), STELA (Single Telomere Length Analysis) and Others), Condition (Cardiovascular Disease, Metabolic Disorders, Cancer, Inflammatory Conditions, Musculoskeletal Disorders, Neurological Conditions, Hepatitis-C Complications, Immunology-Related Conditions and Others), Sample Collection Sites (Hospital, Homes, Diagnostic Laboratories, Offices and Others), Distribution Channel (Direct Tenders, Retail Sales and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Europe Health Screening Market
Europe health screening market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 10.8% in the forecast period of 2021 to 2028 and is expected to reach USD 141,824.23 million by 2028. The rising number of chronic diseases, geriatric population, and increasing awareness about early detection and treatment of disease are the major drivers that propelled the market's demand in the forecast period.
Health screening is an important method of early detection of a specific disorder. The screening tests are often used in preventative medicine to identify whether an individual shows early signs of a condition's risk factors. The disease, which may be detected by screening includes cancer, diabetes, high cholesterol, high blood pressure, and osteoporosis. A surge in the volume of chronic disease, geriatric population, increasing awareness about early detection and treatment of disease is propelling the growth of the health screening market.
The rising awareness among people about early detection and treatment of disease and increasing health expenditure are increasing the demand for health screening.
Rising demand for health screening because of its efficacy, growing number of service providers, and increasing awareness campaign by private and public players of health screening are propelling the growth of the health screening market in the forecast period hence acting as opportunity for the market. However, the high cost of screening test may hamper the market growth in the forecast period.
The Europe health screening market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.
Europe Health Screening Market Scope and Market Size
Europe health screening market is segmented into eight notable segments, which are based on test type, package type, panel type, sample type, technology, condition, sample collection sites, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of test type, Europe health screening market is segmented into cholesterol tests, diabetes test, cancer screening, general checkup test, STDs, blood pressure test, and others. In 2021, cholesterol test segment is expected to dominate the market due to increase awareness about risk associated with high cholesterol level in the population.
- On the basis of package type, the Europe health screening market is segmented into basic health screening, senior citizen profile, women health check, men health check, heart check, diabetes check, and others. In 2021, basic health screening segment is expected to dominate the market because of the various health program organized by the government and by the service providers.
- On the basis of panel type, Europe health screening market is segmented into multi-test panels and single-test panels. In 2021, multi-test panels segment is expected to dominate the market due to advancement in multi test panel for detecting various diseases at a small interval of time.
- On the basis of sample type, the Europe health screening market is segmented into blood, urine, serum, saliva, and others. In 2021, blood segment is expected to dominate the market because blood test can help identify how well the organs are working such as heart, kidneys, and liver among others.
- On the basis of technology, the Europe health screening market is segmented into immunoassays, medical imaging, QPCR (Quantitative Polymerase Chain Reaction), Q-FISH (Quantitative Fluorescence, in situ hybridization), TRF (Terminal Restriction Fragment), STELA (Single Telomere Length Analysis), and others. In 2021, immunoassays segment is expected to dominate the market because immunoassays are contributing in approval for various new screening product in the region which tend to increase the market size in Europe.
- On the basis of condition, the Europe health screening market is segmented into cardiovascular disease, metabolic disorders, cancer, inflammatory conditions, musculoskeletal disorders, neurological conditions, Hepatitis-C complications, immunology-related conditions, and others. In 2021, cardiovascular disease segment is expected to dominate the market because of high prevalence of cardiovascular diseases in European region
- On the basis of sample collection sites, the Europe health screening market is segmented into hospitals, homes, diagnostic laboratories, offices, and others. In 2021, hospitals segment is expected to dominate the market due to the patient centered healthcare services in Europe
- On the basis of distribution channel, the Europe health screening market is segmented into direct tenders, retail sales, and others. In 2021, direct tender segment is expected to dominate the market of the majority of market player operating directly in European region
Europe Health Screening Market Country Level Analysis
Europe health screening market is analyzed, and market size information is provided on the test type, package type, panel type, sample type, technology, condition, sample collection sites, and distribution channel.
The countries covered in the Europe health screening market report are France, U.K., Italy, Germany, Spain, Russia, Turkey, Netherlands, Switzerland, Belgium, Rest of Europe. Germany in the European region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of the rising approval of screening products in European region and the increasing geriatric population.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Geriatric Population and Product Approval in Bigger Market Growth of Europe Health Screening Market
The Europe health screening market also provides you with detailed market analysis for every country's growth in the screening products industry with product sales, the impact of advancement, technology, and changes in regulatory scenarios with their support for the health screening market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and Europe Health Screening Market Share Analysis
Europe health screening market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points are only related to the company’s focus on the Europe health screening market.
The major companies which are dealing in the Europe health screening market are Sonic Healthcare Limited, Quest Diagnostics Incorporated, Healius Limited, Eurofins Scientific, GRAIL, , Exact Sciences Corporation, SYNLAB International GmbH, UNILABS, LabPLUS, BioReference Laboratories, , ACM Global Laboratories, Cerba Healthcare, Quidel Corporation, Innova Medical Group, AMEDES Holding GmbH, RadNet, Inc., Natera, Inc., Trinity Biotech, Nuffield Health, RepeatDx, NeoGenomics Laboratories, H.U Group Holdings, Inc., Lifelabs, ARUP Laboratories, Q2 Solutions, Genova Diagnostics, Life Length, DNA Labs India, , Telomere Diagnostics, Charles River Laboratories, Ambry Genetics, SpectraCell Laboratories, Inc., Dr. Lal PathLabs, and Laboratory Corporation of America among others.
Many events, webinars, and agreements are also initiated by companies worldwide, which also accelerates the Europe health screening market.
For instances,
- In September 2021, Eurofins Scientific announced that its subsidiary Transplant Genomics has launched omnigraf, the only combination biomarket panel that provides the earliest indication of rejection in kidney transplant recipients. This will increase the product portfolio of the company
- In October 2018, Eurofins Scientific announced that it has acquired EnvironeX Group Inc. (EnvironeX), from Marc Hamilton and Persistence Capital Partners. This will help the company to increase its testing capabilities.
Events, publication, agreement, and other strategies by the market player are enhancing the company market in the hunter syndrome treatment market, which also benefits organizations to improve their offering for health screening services.
SKU-